Biguanide

Biguanide is an orally active antihyperglycemic agent. Biguanide inhibits mitochondrial ATP production, activates the LKB1-AMPK signaling pathway, and damages the energy homeostasis. Biguanide enhances insulin-receptor activation and downstream signaling. Biguanide exhibits potential in ameliorating the type 2 diabetes and the insulin-associated cancers[1].

Product Specifications

CAS Number

[56-03-1]

UNSPSC

12352211

Hazard Statement

H302-H315-H318-H335

Target

AMPK; Insulin Receptor; Mitochondrial Metabolism

Type

Reference compound

Related Pathways

Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR; Protein Tyrosine Kinase/RTK

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/biguanide.html

Purity

98.07

Solubility

DMSO : 50 mg/mL (ultrasonic;warming;heat to 60°C)

Smiles

NC(NC(N)=N)=N

Molecular Formula

C2H7N5

Molecular Weight

101.11

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) . 2010 Sep;3 (9) :1060-5.|[2]Di Magno, L., et al., (2022) . The Mechanism of Action of Biguanides: New Answers to a Complex Question. Cancers, 14 (13), 3220.